Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Over the past decade, remarkable advances have been witnessed in the development of
small-molecule probes. These molecular tools have been widely applied for interrogating …

Immunotherapy has revolutionized the treatment of both hematological malignancies and
solid tumors. The use of immunotherapy has improved outcome for patients with cancer …

Targeted therapy and immunotherapy have revolutionized cancer treatment. However, the
ability of cancer to evade the immune system remains a major barrier for effective treatment …

Targeting of PARP enzymes has emerged as an effective therapeutic strategy to selectively
target cancer cells with deficiencies in homologous recombination signaling. Currently used …

The lack of efficient [18F] fluorination processes and target-specific organofluorine
chemotypes remains the major challenge of fluorine-18 positron emission tomography …

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the addition
of poly (ADP-ribose)(PAR) subunits onto themselves and other acceptor proteins. PARPs …

Poly (ADP-ribose) polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the
nuclei of mammalian cells, with a structure and function that have attracted interest since its …